Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ImExHS Limited ( (AU:IME) ) has shared an update.
IMEXHS Limited announced the successful deployment of its new software platform, Aquila+, which is AI-enabled and designed to enhance productivity, data security, and cost efficiency. Despite economic uncertainties, particularly in Latin America, the company remains unaffected by tariffs and is focused on expanding its market presence. The company has also addressed working capital pressures in its Radiology Services business by settling a long-standing debtor issue, allowing it to focus on growth.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
IMEXHS Limited is an innovative provider of medical imaging software and radiology services, operating in 18 countries including Colombia, the US, and Australia. Founded in 2012, the company offers cloud-based, vendor-neutral imaging solutions such as PACS, RIS, CIS, and APLIS, designed to enhance productivity and patient outcomes. IMEXHS focuses primarily on the Latin American market, with Colombia as its largest client base, and is expanding into Mexico, Ecuador, and Peru.
Average Trading Volume: 23,452
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$17.52M
Learn more about IME stock on TipRanks’ Stock Analysis page.